Kestra Medical Technologies (NASDAQ:KMTS) Director Sells $97,502.40 in Stock

Posted by Brian Himes on Oct 1st, 2026

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS – Get Free Report) Director Raymond Cohen sold 3,330 shares of the firm’s stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $29.28, for a total transaction of $97,502.40. Following the sale, the director owned 54,790 shares of the company’s stock, valued at approximately $1,604,251.20. This represents a 5.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Down 4.2%

KMTS traded down $1.18 on Thursday, reaching $27.11. 371,350 shares of the company traded hands, compared to its average volume of 346,206. The company has a market cap of $1.61 billion, a price-to-earnings ratio of -10.15 and a beta of 0.62. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.69 and a quick ratio of 4.69. The stock’s 50 day moving average price is $25.59 and its 200-day moving average price is $22.93. Kestra Medical Technologies, Ltd. has a 52-week low of $17.34 and a 52-week high of $30.00.

Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report) last released its earnings results on Monday, September 14th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.14). Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%.The company had revenue of $30.97 million during the quarter. On average, sell-side analysts expect that Kestra Medical Technologies, Ltd. will post -2.45 EPS for the current fiscal year.

Analysts Set New Price Targets

KMTS has been the topic of a number of recent research reports. Weiss Ratings upgraded Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, September 16th. Piper Sandler reaffirmed an “overweight” rating on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. Oppenheimer assumed coverage on Kestra Medical Technologies in a report on Tuesday, July 21st. They set a “market perform” rating for the company. Wolfe Research set a $30.00 price target on Kestra Medical Technologies in a research note on Wednesday, July 15th. Finally, BTIG Research reaffirmed a “buy” rating and set a $32.00 price objective on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Kestra Medical Technologies has a consensus rating of “Hold” and a consensus price target of $28.38.

View Our Latest Analysis on Kestra Medical Technologies

Hedge Funds Weigh In On Kestra Medical Technologies

Hedge funds have recently bought and sold shares of the business. Corient Private Wealth LP raised its holdings in Kestra Medical Technologies by 284.2% during the second quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock valued at $1,542,000 after buying an additional 44,839 shares in the last quarter. California State Teachers Retirement System boosted its stake in shares of Kestra Medical Technologies by 39.2% during the 1st quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock worth $555,000 after acquiring an additional 7,844 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Kestra Medical Technologies by 6.6% during the 1st quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock valued at $1,844,000 after acquiring an additional 5,731 shares during the last quarter. Quantinno Capital Management LP bought a new position in shares of Kestra Medical Technologies in the 1st quarter valued at approximately $431,000. Finally, Sei Investments Co. lifted its holdings in Kestra Medical Technologies by 22.6% in the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock worth $4,726,000 after purchasing an additional 43,753 shares during the last quarter.

Kestra Medical Technologies Company Profile

(Get Free Report)

Kestra Medical Technologies, Inc is a medical device company focused on developing and commercializing technologies for patients at risk of sudden cardiac arrest. The company’s primary product is the ASSURE wearable cardioverter defibrillator, a wearable system designed to continuously monitor a patient’s heart rhythm and deliver an electrical shock when a life-threatening arrhythmia is detected.

The ASSURE system is intended to provide temporary protection for patients who may be at elevated risk of sudden cardiac death but are not yet candidates for, or are awaiting, an implantable cardioverter-defibrillator.